Restricted intake of dietary advanced glycation end products retards renal progression in the remnant kidney model

Kidney International

Volumn 71, Issue 9, 2007, Pages 901-911

  Feng, J X ^a   Hou, F F ^a   Liang, M ^a   Wang, G B ^a   Zhang, X ^a   Li, H Y ^a   Xie, D ^a   Tian, J W ^a   Liu, Z Q ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

AGEs; Diet; Renal dysfunction; Renal fibrosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CREATININE; GLUTATHIONE PEROXIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE VARIABILITY; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DIET; DIET RESTRICTION; DISEASE COURSE; DOWN REGULATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; KIDNEY FAILURE; KIDNEY FIBROSIS; MACROPHAGE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; STATISTICAL SIGNIFICANCE;

EID: 34247547940     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002162     Document Type: Article

References (45)

1. Collins AJ, Couser WG, Dirks JH et al. World kidney day: an idea whose time has come. Kidney Int 2006; 69: 781-782.
2. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
3. Vlassara H, Palace MR. Diabetes and advanced glycation end products. J Intern Med 2002; 251: 87-101.
4. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N (epsilon)-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-468.
5. Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000; 76(Suppl): S120-S125.
6. Weiss MF, Erhard P, Kader-Attia FA et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000; 57: 2571-2585.
7. Henle T. AGEs in foods: do they play a role in uremia? Kidney Int 2003; 84(Suppl): 145-147.
8. Hofmann SM, Dong HJ, Li Z et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002; 51: 2082-2089.
9. Uribarri J, Peppa M, Cai W et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-731.
10. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 2000; 35: 365-380.
11. Hou FF, Owen Jr WF. Beta 2-microglobulin amyloidosis: role of monocytes/macrophages. Curr Opin Nephrol Hypertens 2002; 11: 417-421.
12. Hou FF, Miyata T, Boyce J et al. Beta(2)-microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int 2001; 59: 990-1002.
13. Vlassara H, Striker LJ, Teichberg S et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704-11708.
14. Foerster A, Henle T. Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): studies on the urinary excretion of pyrraline. Biochem Soc Trans 2003; 31: 1383-1385.
15. ε-carboxymethyllysine. Czech J Food Sci 2000; 18: 116-119.
16. Hou FF, Ren H, Owen Jr WF et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1889-1896.
17. Šebeková K, Faist V, Hofmann T et al. Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. Am J Kidney Dis 2003; 41: S48-S51.
18. Hou FF, Boyce J, Chertow GM et al. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol 1998; 9: 277-283.
19. Fu MX, Requena JR, Jenkins AJ et al. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982-9986.
20. Cai W, Cao QD, Zhu L et al. Oxidative stress-induced carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8: 337-346.
21. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146.
22. Dittrich R, Hoffmann I, Stahl P et al. Concentrations of Nepsilon-carboxymethyllysine in human breast milk, infant formulas, and urine of infants. J Agric Food Chem 2006; 54: 6924-6928.
23. Grunwald S, Krause R, Bruch M et al. Transepithelial flux of early and advanced glycation compounds across Caco-2 cell monolayers and their interaction with intestinal amino acid and peptide transport systems. Br J Nutr 2006; 95: 1221-1228.
24. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999; 48: 1308-1315.
25. Howard BV, Wylie-Rosett J. Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2002; 106: 523-527.
26. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-17.
27. Cohen EP, Robbins ME, Whitehouse E, Hopewell JW. Stenosis of the tubular neck: a possible mechanism for progressive renal failure. J Lab Clin Med 1997; 129: 567-573.
28. Huang JS, Chuang LY, Guh JY et al. Effect of nitric oxide-cGMP-dependent protein kinase activation on advanced glycation end-product-induced proliferation in renal fibroblasts. J Am Soc Nephrol 2005; 16: 2318-2329.
29. Thomas MC, Tikellis C, Burns WM et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-2984.
30. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000; 11: 152-176.
31. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990; 86: 453-462.
32. Koschinsky T, He CJ, Mitsuhashi T et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-6479.
33. Peppa M, Brem H, Ehrlich P et al. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003; 52: 2805-2813.
34. Wrobel K, Wrobel K, Garay-Sevilla ME et al. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 1997; 43: 1563-1569.
35. Lott JA, Stephan VA, Pritchard Jr KA. Evaluation of the Coomassie Brilliant Blue G-250 method for urinary protein. Clin Chem 1983; 29: 1946-1950.
36. Levey AS. Clinical evaluation of renal function. In: Greenberg A (ed). Primer on Kidney Diseases, 2nd edn. Academic Press: San Diego, CA, USA, 1998, pp 20-26.
37. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-143.
38. Miyazaki T, Aoyama I, Ise M et al. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 2000; 15: 1773-1781.
39. Ots M, Mackenzie HS, Troy JL et al. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998; 9: 224-230.
40. Badid C, Vincent M, McGregor B et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61.
41. Taal MW, Chertow GM, Rennke HG et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol 2001; 280: F343-F355.
42. Taal MW, Zandi-Nejad K, Weening B et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 2000; 58: 1664-1676.
43. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-216.
44. Flohe L, Gunzler WA. Assays of glutathione peroxidase. Methods Enzymol 1984; 105: 114-121.
45. Liu SX, Hou FF, Guo ZJ et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1156-1162.